RxDoctor Payments Data

Juan Martinez-Vargas, MD

Internal Medicine · Tallahassee, FLNPI 1558704528

Payments from drug & device makers

$1,725in general payments, 2019–2025

Across 31 payments — averaging $55.65 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bayer$221
  • Lilly USA, LLC$221
  • AstraZeneca$220
  • Boehringer Ingelheim$205
  • Cvrx, Inc.$168
  • Medtronic$166
  • plus $524 from 7 others

What the payments were for

  • Food & beverage$1,725100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,725 in reported general payments places this provider in the 75th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$115,372
Medicare patients
249
Services billed
1,805

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide155$205,995
EliquisApixaban134$146,406
MounjaroTirzepatide115$134,201
FarxigaDapagliflozin Propanediol102$105,636
JardianceEmpagliflozin79$71,240
JanuviaSitagliptin Phosphate35$43,057
LinzessLinaclotide38$36,920
Repatha SureclickEvolocumab37$30,642
KerendiaFinerenone22$23,404
MyrbetriqMirabegron23$20,441
Trelegy ElliptaFluticasone/Umeclidin/Vilanter27$20,137
TrulicityDulaglutide19$18,226
Breztri AerosphereBudesonide/Glycopyr/Formoterol15$17,748
RybelsusSemaglutide11$14,556
Humalog Kwikpen U-100Insulin Lispro51$12,428

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$21$220,552166 claims
Lilly USA, LLCMounjaro, Trulicity$221$152,427134 claims
PfizerEliquis$123$146,406134 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$220$137,223155 claims
Boehringer IngelheimJardiance$205$71,24079 claims
BayerKerendia$221$23,40422 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Tallahassee

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →